Our findings establish a novel CHML-SLC44A3-choline metabolic axis that drives HCC progression through coordinated transcriptional and metabolic reprogramming, revealing actionable therapeutic targets for clinical translation. Here, CHML is linked to hepatocellular carcinoma.